Post
AAN 2024: AbbVie highlights long-term safety of atogepant in migraine prevention
At the American Academy of Neurology (AAN) 2024, AbbVie highlighted the long-term safety data of Qulipta (atogepant) for the preventive …
AAN 2024: Biomarker data shows promise for Alzheon’s oral anti-amyloid drug
On 15 April at the American Academy of Neurology (AAN) 2024 Annual Meeting, during a scientific platform session titled 'Emerging …
AAN 2024: Amneal showcases IPX203’s safety profile in anticipation of FDA approval
At the American Academy of Neurology (AAN) 2024 Annual Meeting, Amneal Pharmaceuticals presented new safety data for IPX203 (carbidopa + …
Ultimovacs downsizes to funnel funds to cancer vaccine programme
Ultimovacs has implemented cash-saving strategies, including a 40% workforce reduction, to extend its reserves into Q4 2025. The operational adjustments are …
Volastra Therapeutics initiates dosing in Phase Ib ovarian cancer trial
Volastra Therapeutics has announced the dosing of the first subject in a Phase Ib clinical trial of sovilnesib for patients …
Arrivo Bio doses first subject in Phase IIb major depressive disorder trial
Arrivo Bio has dosed the first subject in a Phase IIb SP-624-202 clinical trial of SP-624, a SIRT6 activator to …
QT imaging’s breast imaging system proves as effective as mammography
Medical device company QT Imaging Holdings has announced positive data demonstrating that its Breast Acoustic CT scan imaging technique can …
AstraZeneca’s Imfinzi shows overall survival benefit in Phase III BTC trial
AstraZeneca has announced updated exploratory results from the TOPAZ-1 Phase III clinical trial, indicating that Imfinzi (durvalumab) plus standard-of-care chemotherapy …
Bayer and AskBio report data from Parkinson’s disease therapy trial
Bayer and its subsidiary Asklepios BioPharmaceutical (AskBio) have reported data from an 18-month Phase Ib clinical trial of a gene …
Decentralized clinical trials – no “one size fits all”
The hype around decentralized clinical trials (DCTs) continues to rise in the healthcare industry but sponsors have been reminded that …
Digital twin market to surpass $150bn by 2030, impacting many industries
The digital twin market will be worth $154bn by 2030 having expanded at a compound annual growth rate of 35.6% …
Harnessing the power of cell and gene therapy in oncology
By 2029, the global cell and gene therapy market is projected to be worth more than $81bn, according to GlobalData’s …
New WHO hepatitis B guidelines address testing and treatment barriers
The World Health Organization (WHO) announced an update to guidance on the prevention, diagnosis, and treatment of chronic hepatitis B …
Changing epidemiology of atopic dermatitis in South Korea
The epidemiology of atopic dermatitis (AD) is heterogeneous across countries and age groups. Traditionally, AD in South Korea has always …
AAN 2024: Myostatin inhibitors on the horizon for the treatment of SMA
At the American Academy of Neurology (AAN) 2024 Annual Meeting, Biohaven presented its Phase III RESILIENT trial (NCT05337553), which investigates …